Uekado Y, Hirano A, Inagaki T, Hiroi A, Watanabe T
Dept. of Urology, Wakayama Medical College.
Gan To Kagaku Ryoho. 1995 Jul;22(8):1041-5.
From November 1984 to December 1993, 72 patients with newly diagnosed, stage C or D prostate cancer were treated with chemohormonal therapy consisting of CDDP, CPM, diethylstilbestrol diphosphate and orchiectomy. Forty-four of 72 patients (61%) had partial response 3 months after the initiation of the treatment. A good response rate was observed in prostate gland and tumor markers (63% and 81%), but the response rate was poor in bone and other soft tissure metastasis (17% and 18%). Subjective symptoms improved in 82% of the pain, 70% of the infravesical obstruction, 65% of the performance status, and 5% of the body weight. The 5-year survival rate was 66%. The prognosis of the patients with poorly differentiated carcinoma or high Gleason score tumor was poor. Survival rate was no different between stage C and D. Relapse occurred in 16 patients (22%) and tended to occur in the patients with poorly differentiated carcinoma, high Gleason score tumor, stage D2 or stable disease. The survival rate was better, and the relapse rate lower than in the 35 patients with hormonal treatment alone during the same period, but no significant difference was observed between the two groups.
1984年11月至1993年12月，72例新诊断的C期或D期前列腺癌患者接受了由顺铂、环磷酰胺、己烯雌酚二磷酸酯和睾丸切除术组成的化学激素治疗。72例患者中有44例（61%）在治疗开始3个月后出现部分缓解。前列腺和肿瘤标志物的缓解率良好（分别为63%和81%），但骨和其他软组织转移的缓解率较差（分别为17%和18%）。82%的疼痛、70%的膀胱颈以下梗阻、65%的体能状态和5%的体重的主观症状有所改善。5年生存率为66%。低分化癌或高Gleason评分肿瘤患者的预后较差。C期和D期患者的生存率无差异。16例患者（22%）出现复发，且低分化癌、高Gleason评分肿瘤、D2期或病情稳定的患者更容易复发。生存率高于同期仅接受激素治疗的35例患者，复发率低于这些患者，但两组之间未观察到显著差异。
